Table 1.
Baseline characteristics of DLBCL patients completed 3 cycles of (R)-CHOP chemotherapy
| All patients | No-AISC | AISC | P-value | |
|---|---|---|---|---|
| N = 70 | N = 44 | N = 26 | ||
| Age (year) | 55.47 ± 13.63 | 55.50 ± 14.86 | 55.42 ± 11.54 | 0.982 |
| Male/female (n) | 33/37 | 20/24 | 13/13 | 0.713 |
| BMI (kg/m2) | 22.85 ± 3.31 | 22.12 ± 3.20 | 24.10 ± 3.18 | 0.014 |
| Smoking(%) | 17 (24.29) | 7 (15.91) | 10 (38.46) | 0.033 |
| GLS (-%) | 20.04 ± 2.24 | 19.73 ± 2.29 | 20.58 ± 2.08 | 0.125 |
| E (cm/s) | 67.79 ± 13.01 | 66.01 ± 11.47 | 70.81 ± 15.01 | 0.137 |
| e’(cm/s) | 7.27 ± 2.03 | 6.92 ± 1.98 | 7.85 ± 2.02 | 0.067 |
| LDL-C (mmol/L) | 2.56 ± 0.77 | 2.42 ± 0.68 | 2.80 ± 0.85 | 0.046 |
| NT-proBNP (ng/L) | 54.00 (31.00, 127.00) | 70.50 (32.25, 132.25) | 41.50 (24.25, 76.50) | 0.070 |
| TC (mmol/L) | 4.19 ± 0.93 | 4.07 ± 0.86 | 4.39 ± 1.02 | 0.168 |
| TG (mmol/L) | 1.36 (1.02, 1.68) | 1.25 (0.91, 1.55) | 1.54 (1.27, 1.92) | 0.009 |
Values are expressed as mean ± standard deviation, n (%), or median (Q1-Q3). Bold values indicate statistical significance (P < 0.05)
AISC Anthracycline-induced subclinical cardiotoxicity, BMI Body mass index, DLBCL Diffuse large-B cell lymphoma, E mitral inflow E velocity, e’ mitral e’ velocity, GLS Global longitudinal peak systolic strain, LDL-C Low-density lipoprotein cholesterol, NT-proBNP N terminal-pro brain natriuretic peptide, TC Total triglyceride, TG Total cholesterol